Visual function linked to preBCVA in AMD cataract patients

Article

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Visual function improves in eyes with age-related macular degeneration (AMD) that have undergone cataract surgery, but the extent of the improvement depends on the eye’s preoperative best-corrected visual acuity (preBCVA), according to a new retrospective analysis published in Investigative Ophthalmology and Visual Science.

Related: Radiotherapy system receives CE mark extension

The US investigators studied 4,924 cataract surgeries on eyes with AMD for which preoperative and postoperative NEI-VFQ-25 questionnaires had been submitted. All were from the VA Ophthalmic Surgical Outcomes Data Project. The researchers compared outcomes in these eyes with outcomes in control eyes that did not have retinal pathology, looking at changes in visual acuity and improvement in overall visual function and its subscales.

Analysing overall scores, the investigators found that, for eyes with a preBCVA of ≥20/40, the improvement in visual function was similar to that seen in patients without retinal pathology. If the eye’s preBCVA was <20/40, however, then there was a lesser degree of improvement; the amount of improvement decreased with decreasing preBCVA. 

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.